Ignite Creation Date:
2024-05-06 @ 3:11 PM
Last Modification Date:
2024-10-26 @ 1:44 PM
Study NCT ID:
NCT04547465
Status:
UNKNOWN
Last Update Posted:
2023-08-08
First Post:
2020-09-06
Brief Title:
2D Speckle-tracking Echocardiography in Chemotherapy-induced Cardiomyopathy With Cardiovascular Risk Factors
Sponsor:
Gia Dinh People Hospital
Organization:
Gia Dinh People Hospital
Study Overview
Official Title:
The Role of 2D Speckle-tracking Echocardiography in Diagnosis Chemotherapy-induced Cardiomyopathy in Breast Cancer Patients With High Cardiovascular Risk Factors
Status:
UNKNOWN
Status Verified Date:
2022-08
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aims of this study is to evaluate the role of 2D speckle-tracking echocardiography in diagnosis chemotherapy related left ventricular dysfunction in breast cancer patients with cardiovascular risks
Detailed Description:
Chemotherapy induced cardiomyopathy is a serious adverse effect of anticancer treatments with poor long-term prognosis In addition to the cumulative dose of anthracycline and trastuzumab cardiovascular risks have been proven to be the second hit when dealing with chemotherapy related cardiomyopathy in breast cancer patients Speckle-tracking echocardiography have had robust evidence in diagnosis the early stage of left ventricular dysfunction in various types of cancer treated by cardiotoxicity drugs However data is still lacking regarding the role of speckle-tracking echocardiography in breast cancer patients with cardiovascular risk
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None